sptbn4

sptbn4

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">sptbn4</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SPTBN4</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Spectrin Beta Non-Erythrocytic 4 (βIV-Spectrin)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19q13.13</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[10529](https://www.ncbi.nlm.nih.gov/gene/10529)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607666](https://omim.org/entry/607666)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000197894</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q9H6G1](https://www.uniprot.org/uniprot/Q9H6G1)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>βIV-spectrin, KIAA1762</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>ALS, CMT, neurodevelopmental disorders</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">CNS neurons</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">PNS neurons</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Low</td>
</tr>
<tr>
<td class="label">astrocytes</td>
<td>Not expressed</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Type</td>
</tr>
<tr>
<td class="label">p.Arg501*</td>
<td>Nonsense</td>
</tr>
<tr>
<td class="label">p.Leu1612Pro</td>

sptbn4

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">sptbn4</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SPTBN4</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Spectrin Beta Non-Erythrocytic 4 (βIV-Spectrin)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19q13.13</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[10529](https://www.ncbi.nlm.nih.gov/gene/10529)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607666](https://omim.org/entry/607666)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000197894</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q9H6G1](https://www.uniprot.org/uniprot/Q9H6G1)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>βIV-spectrin, KIAA1762</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>ALS, CMT, neurodevelopmental disorders</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">CNS neurons</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">PNS neurons</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Low</td>
</tr>
<tr>
<td class="label">astrocytes</td>
<td>Not expressed</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Type</td>
</tr>
<tr>
<td class="label">p.Arg501*</td>
<td>Nonsense</td>
</tr>
<tr>
<td class="label">p.Leu1612Pro</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">p.Arg2007Gln</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">c.7508_7509del</td>
<td>Frameshift</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Ortholog</td>
</tr>
<tr>
<td class="label">Human</td>
<td>SPTBN4</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>Sptbn4</td>
</tr>
<tr>
<td class="label">Zebrafish</td>
<td>sptbn4</td>
</tr>
<tr>
<td class="label">Drosophila</td>
<td>β-Spec</td>
</tr>
</table>

{{.infobox .infobox-gene}}

Overview

SPTBN4 encodes betaIV-spectrin, a specialized spectrin isoform that localizes specifically to the axon initial segment (AIS) and nodes of Ranvier in neurons["@berg2019"][@zuccotti2012]. The spectrin membrane skeleton provides structural support to the plasma membrane and organizes critical membrane microdomains. In neurons, betaIV-spectrin partners with alphaIV-spectrin to form a specialized cytoskeletal scaffold that anchors voltage-gated sodium channels (Nav1.2, Nav1.6), voltage-gated potassium channels, and the critical scaffold protein AnkyrinG at the AIS["@komada2006"][@wojtkowski2021].

The AIS is a specialized neuronal compartment located at the proximal axon that serves as the primary site of action potential initiation in most neurons. Proper organization of the AIS is essential for:

• Action potential generation — the high density of sodium channels enables reliable spike initiation
• Saltatory conduction — along myelinated axons, nodes of Ranvier enable rapid signal transmission
• Neuronal polarity — the AIS maintains the distinction between axon and dendrites
• Homeostatic plasticity — neurons can modulate AIS position and length to tune excitability

Gene Structure and Protein

The [SPTBN4](/genes/sptbn4) gene is located on chromosome 19q13.13 and encodes a 2,724-amino acid protein. βIV-spectrin is expressed primarily in the nervous system as multiple splice isoforms, with the longest isoform (βIV-spectrin) containing:

• N-terminal actin-binding domain — interacts with F-actin
• Spectrin repeat domains — 17 spectrin repeats forming the central rod domain
• PH domain — phospholipid binding
• C-terminal domain — mediates dimerization and interactions

Molecular Function

AIS Organization

βIV-spectrin's primary function is organizing the axon initial segment[@berg2019][@leterrier2015]:

AnkyrinG recruitment: βIV-spectrin directly binds to AnkyrinG through a specialized binding motif. This interaction is essential for clustering AnkyrinG at the AIS, which in turn anchors the voltage-gated sodium channels.

Sodium channel anchoring: The βIV-spectrin/AnkyrinG complex provides the docking site for voltage-gated sodium channels (Nav1.2, Nav1.6). Mutations affecting this anchoring cause severe neuronal dysfunction.

Cytoskeletal scaffold: βIV-spectrin links the membrane proteins to the actin cytoskeleton, providing mechanical stability to the AIS membrane.

Node of Ranvier Organization

AtNodes of Ranvier, βIV-spectrin plays a similar organizational role:

paranodal junctions: βIV-spectrin helps organize the paranodal region where axons contact myelin-forming glial cells.

Sodium channel clustering: Nav1.6 channels are highly concentrated at the nodes, requiring βIV-spectrin for proper localization.

Saltatory conduction: The precise organization of ion channels at nodes is essential for the rapid, energy-efficient saltatory conduction of action potentials.

Signaling Platform

Beyond structural roles, the βIV-spectrin scaffold participates in signaling:

Second messenger signaling: The spectrin meshwork sequesters signaling molecules near the membrane.

Cytoskeletal regulation: βIV-spectrin interacts with Rho GTPases and other regulators of the actin cytoskeleton.

Protein quality control: The AIS contains specialized degradation machinery, and βIV-spectrin may participate in this process.

Tissue Expression

SPTBN4 is expressed exclusively in the nervous system:

Specific neuronal populations with high βIV-spectrin expression:

• Cortical pyramidal neurons — layer 2/3, layer 5
• Hippocampal CA1 pyramidal neurons
• Cerebellar Purkinje cells
• Spinal cord motor neurons — particularly relevant to ALS
• Dorsal root ganglion neurons
• Dopaminergic neurons of the substantia nigra

Disease Associations

Amyotrophic Lateral Sclerosis (ALS)

βIV-spectrin dysfunction may contribute to [ALS](/diseases/amyotrophic-lateral-sclerosis) pathogenesis[@galiano2012]:

AIS disruption: In ALS models, the AIS shows progressive disorganization before overt neurodegeneration. βIV-spectrin loss may compromise sodium channel clustering and neuronal excitability.

Axonal transport deficits: The spectrin cytoskeleton supports axonal transport. Disruption may impair delivery of essential cargoes to distal axons.

Motor neuron vulnerability: Motor neurons have extremely long axons requiring robust cytoskeletal infrastructure. βIV-spectrin mutations or dysfunction may render motor neurons particularly susceptible.

Dysregulated excitability: ALS neurons often show hyperexcitability, which may relate to AIS remodeling.

Charcot-Marie-Tooth Disease

SPTBN4 variants cause a form of [Charcot-Marie-Tooth disease](/diseases/charcot-marie-tooth) (CMT):

Clinical features:

• Peripheral neuropathy
• Distal muscle weakness and atrophy
• Reduced deep tendon reflexes
• Foot deformities (pes cavus, hammertoes)

Neurodevelopmental Disorders

Dominant [SPTBN4](/genes/sptbn4) mutations cause neurodevelopmental disorders[@hanlon2018]:

Clinical features:

• Developmental delay
• Intellectual disability
• Neuromyotonia (continuous muscle fiber activity)
• Hypotonia
• Speech impairment

Other Neurological Conditions

• Epilepsy — AIS dysfunction may lower seizure threshold
• Autism spectrum disorder — altered neuronal connectivity
• Schizophrenia — possible AIS abnormalities
• Spinal muscular atrophy — overlap with cytoskeletal genes

Genetic Variants

Pathogenic Variants

GWAS Associations

• ALS susceptibility
• Peripheral neuropathy severity

Interaction Networks

Core Protein Interactions

• αIV-spectrin (SPTAN1) — heterodimer formation
• AnkyrinG (ANK3) — primary binding partner
• Nav1.2/SCN2A — anchoring
• Nav1.6/SCN8A — anchoring
• NF186/NRXN1 — AIS adhesion
• Caspr2/CNTNAP2 — paranodal junctions

Pathway Membership

• Axon initial segment complex
• Spectrin cytoskeleton
• Voltage-gated sodium channel complex
• Axonal transport
• Neuronal polarity establishment

Research Directions

Outstanding Questions

Emerging Areas

• Gene therapy: AAV delivery of wild-type SPTBN4
• Small molecules: AIS-stabilizing compounds
• iPSC models: Patient-derived motor neurons

Clinical Presentation

ALS Phenotypes

βIV-spectrin dysfunction in ALS manifests in specific ways:

Limb-onset ALS: Most common form, starting in upper or lower limbs. Early AIS disruption may contribute to fasciculations and cramps.

Bulbar-onset ALS: Initial symptoms in facial muscles. AIS dysfunction may accelerate corticobulbar tract degeneration.

Respiratory onset: Rare presentation with early diaphragm weakness. Phrenic nerve motor neurons are particularly vulnerable.

CMT Phenotypes

SPTBN4-related CMT shows characteristic features:

Motor > sensory neuropathy: Motor symptoms predominate early.

Relatively slow progression: Unlike aggressive ALS, CMT progresses over decades.

Foot deformities: Develop over time due to muscle imbalance.

Neurodevelopmental Phenotypes

Neuromyotonia: Continuous muscle fiber activity causing stiffness, myotonia, and muscle rippling.

Developmental trajectory: Delays noted in infancy; intellectual disability varies.

Diagnostic Considerations

Electrophysiology

Key diagnostic findings:

Nerve conduction studies (NCS):

• Reduced compound muscle action potential (CMAP) amplitudes in CMT
• Preserved conduction velocities (demyelinating pattern in some cases)

• Denervation potentials in ALS
• Chronic neurogenic changes in CMT

• Increased jitter in myasthenia gravis (differential diagnosis)
• Normal in SPTBN4 disorders (helps exclude neuromuscular junction disorders)

Imaging

MRI:

• May show spinal cord atrophy in ALS
• Normal in early CMT
• AIS structure visualized with specialized sequences

Genetic Testing

Sequencing approaches:

• Targeted panel for ALS/CMT genes
• Whole exome sequencing for unknown etiologies
• Segregation analysis in families

Therapeutic Approaches

Current Management

ALS standard of care:

• Riluzole (modest survival benefit)
• Edaravone (slows functional decline)
• Multidisciplinary clinic care
• Respiratory support
• Nutritional support
• Assistive devices

• Physical therapy
• Orthotics
• Pain management
• Surgical correction of foot deformities

Investigational Therapies

AIS stabilization:

• Compounds enhancing spectrin-ankyrin interaction
• Sodium channel clustering enhancers
• Cytoskeletal stabilizers

• Antisense oligonucleotides for specific mutations
• AAV-mediated gene delivery
• CRISPR-based gene editing

Comparative Biology

Species Conservation

βIV-spectrin is highly conserved:

Model Systems

Mouse models: Knockout and transgenic mice available.

Zebrafish: Transparent embryos allow AIS visualization.

In vitro systems: Cultured neurons from patient iPSCs.

Future Directions

Biomarker Development

Potential biomarkers for βIV-spectrin disorders:

• Blood spectrin fragments
• Neuronal-specific enolase
• Neurofilament light chain (NfL)
• Imaging biomarkers for AIS integrity

Clinical Trials

Outcome measures:

• ALS Functional Rating Scale-Revised (ALSFRS-R)
• Timed Up and Go test
• Respiratory function tests
• Patient-reported outcomes

Key Publications

See Also

• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Charcot-Marie-Tooth Disease](/diseases/charcot-marie-tooth)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Axon Initial Segment Pathway](/mechanisms/axon-initial-segment)
• [AnkyrinG](/genes/ank3)
• [Sodium Channels](/proteins/nav1-6-channel)

References

[@berg2019]: Berg et al. [The axon initial segment as a membrane domain](https://pubmed.ncbi.nlm.nih.gov/30602728/). Nat Rev Neurosci. 2019;20(2):81-96.

[@komada2006]: Komada et al. [Neuronal spectrin membrane skeleton](https://pubmed.ncbi.nlm.nih.gov/16641945/). J Neurosci. 2006;26(32):8319-8329.

[@stankewicz2020]: Stankewicz et al. [βIV-spectrin mutations causing neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/32856789/). J Neurosci. 2020;40(15):2991-3003.

[@galiano2012]: Galiano et al. [A distal axon injury signature predicts ALS progression](https://pubmed.ncbi.nlm.nih.gov/22728112/). Exp Neurol. 2012;237(2):282-294.

[@zuccotti2012]: Zuccotti et al. [Spectrin functions in neuronal development](https://pubmed.ncbi.nlm.nih.gov/22674684/). Dev Neurobiol. 2012;72(11):1532-1546.

[@wojtkowski2021]: Wojtkowski et al. [Ankyrin-G and spectrin at the axon initial segment](https://pubmed.ncbi.nlm.nih.gov/34052345/). J Cell Biol. 2021;220(4):e202009154.

[@komura2015]: Komura et al. [βIV-spectrin and ankyrin-G cooperate to stabilize the AIS](https://pubmed.ncbi.nlm.nih.gov/26455432/). Cell Rep. 2015;12(10):1609-1620.

[@hanlon2018]: Hanlon et al. [SPTBN4 mutations cause neurodevelopmental disorder](https://pubmed.ncbi.nlm.nih.gov/29348338/). Am J Hum Genet. 2018;103(5):826-834.

[@leterrier2015]: Leterrier et al. [The axon initial segment: the nexus of neuronal polarity](https://pubmed.ncbi.nlm.nih.gov/26422674/). Neuron. 2015;88(5):892-901.

[@ogawa2019]: Ogawa et al. [Spectrin cytoskeleton and AIS plasticity in disease](https://pubmed.ncbi.nlm.nih.gov/31234567/). Neuroscience. 2019;408:277-294.

[@yamagata2022]: Yamagata et al. [Axon initial segment dysfunction in ALS](https://pubmed.ncbi.nlm.nih.gov/35758932/). Acta Neuropathol. 2022;144(3):395-411.

[@jang2017]: Jang et al. [βIV-spectrin and AnkyrinG in neuronal disease](https://pubmed.ncbi.nlm.nih.gov/28254802/). J Neurosci. 2017;37(14):3613-3624.

[@lefranc2018]: Lefranc et al. [Spectrin mutations in Charcot-Marie-Tooth disease](https://pubmed.ncbi.nlm.nih.gov/29481334/). Brain. 2018;141(5):1415-1428.

[@devaux2019]: Devaux et al. [SPTBN4 and neuronal excitability](https://pubmed.ncbi.nlm.nih.gov/31114482/). Front Cell Neurosci. 2019;13:263.

[@benhaddou2020]: Benhaddou et al. [AIS plasticity in health and disease](https://pubmed.ncbi.nlm.nih.gov/33298547/). Neuroscience. 2020;451:287-301.

External Links

• [NCBI Gene: 10529](https://www.ncbi.nlm.nih.gov/gene/10529)
• [Ensembl: ENSG00000197894](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197894)
• [UniProt: Q9H6G1](https://www.uniprot.org/uniprot/Q9H6G1)

Pathway Diagram

The following diagram shows the key molecular relationships involving sptbn4 discovered through SciDEX knowledge graph analysis: